marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-06-2024
UroGen Pharma Ltd. Balance Sheet 2011-2024 | URGN
Annual Balance Sheet UroGen Pharma Ltd.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
3.55 M | 42.1 M | -44 M | -51.4 M | -47.1 M | -101 M | -37 M | -21.4 M | -18 M | - | - | - | - |
Long Term Debt |
98.6 M | 97.5 M | 398 K | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
- | - | - | 1.2 M | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 4.21 M | 2.6 M | - | - | 3.61 M | 872 K | - | - | - | - |
Total Current Liabilities |
31.2 M | 23.9 M | 22.4 M | 21.4 M | 19.5 M | 13.5 M | 7.04 M | - | - | - | - | - | - |
Total Liabilities |
244 M | 225 M | 111 M | 25.6 M | 22.1 M | 13.5 M | 7.04 M | 6.75 M | 3.11 M | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | 650 K | - | - | - | - | - | - |
Retained Earnings |
-679 M | -577 M | -467 M | -357 M | -228 M | -123 M | -47.2 M | -27.2 M | -25.3 M | - | - | - | - |
Total Assets |
178 M | 136 M | 120 M | 122 M | 202 M | 104 M | 75.6 M | 23.1 M | 19.4 M | - | - | - | - |
Cash and Cash Equivalents |
95 M | 55.4 M | 44.4 M | 52.9 M | 49.7 M | 101 M | 37 M | 21.4 M | - | - | - | - | - |
Book Value |
-65.2 M | -89.4 M | 8.41 M | 96.4 M | 180 M | 90.1 M | 68.5 M | 16.3 M | 16.3 M | - | - | - | - |
Total Shareholders Equity |
-65.2 M | -89.4 M | 8.41 M | 96.4 M | 180 M | 90.1 M | 68.5 M | 16.3 M | 16.3 M | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet UroGen Pharma Ltd.
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
122 M | 97.8 M | 97.6 M | 98.6 M | 98.5 M | 98.3 M | 97.9 M | 97.5 M | 71.9 M | 71.2 M | 70.8 M | - | 616 K | 922 K | 398 K | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 2.6 M | 2.6 M | 2.6 M | 2.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.75 M | 1.94 M | 2.18 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
276 M | 252 M | 241 M | 244 M | 236 M | 234 M | 230 M | 225 M | 192 M | 187 M | 183 M | 111 M | 103 M | 97.5 M | 20.9 M | 25.6 M | 25.6 M | 25.6 M | 25.6 M | 22.1 M | 22.1 M | 22.1 M | 22.1 M | 13.5 M | 13.5 M | 13.5 M | 13.5 M | 7.04 M | - | - | - | 6.75 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 86 K | 196 K | 650 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-769 M | -745 M | -712 M | -679 M | -653 M | -631 M | -607 M | -577 M | -548 M | -522 M | -496 M | -467 M | -439 M | -409 M | -382 M | -357 M | -357 M | -357 M | -357 M | -228 M | -228 M | -228 M | -228 M | -123 M | -123 M | -123 M | -123 M | -47.2 M | - | - | - | -27.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
302 M | 282 M | 201 M | 178 M | 194 M | 95.4 M | 113 M | 136 M | 128 M | 146 M | 166 M | 120 M | 135 M | 154 M | 97.4 M | 122 M | 122 M | 122 M | 122 M | 202 M | 202 M | 202 M | 202 M | 104 M | 104 M | 104 M | 104 M | 75.6 M | - | - | - | 23.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
125 M | 220 M | 131 M | 95 M | 119 M | 20.1 M | 36.5 M | 55.4 M | 28.7 M | 80.7 M | 105 M | 44.4 M | 55.3 M | 63.3 M | 40.5 M | 52.9 M | 52.9 M | 52.9 M | 52.9 M | 49.7 M | 49.7 M | 49.7 M | 49.7 M | 101 M | 101 M | 101 M | 101 M | 37 M | 79.2 M | 77.1 M | 18.4 M | 21.4 M | - | - | - | 18 M | - | - | - | 3.87 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
25.5 M | 30.3 M | -40.1 M | -65.2 M | -42 M | -138 M | -117 M | -89.4 M | -63.3 M | -40.9 M | -17.1 M | 8.41 M | 31.5 M | 56.3 M | 76.5 M | 96.4 M | 96.4 M | 96.4 M | 96.4 M | 180 M | 180 M | 180 M | 180 M | 90.1 M | 90.1 M | 90.1 M | 90.1 M | 68.5 M | - | - | - | 16.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
25.5 M | 30.3 M | -40.1 M | -65.2 M | -42 M | -138 M | -117 M | -89.4 M | -63.3 M | -40.9 M | -17.1 M | 8.41 M | 31.5 M | 56.3 M | 76.5 M | 96.4 M | 96.4 M | 96.4 M | 96.4 M | 180 M | 180 M | 180 M | 180 M | 90.1 M | 90.1 M | 90.1 M | 90.1 M | 68.5 M | 76.3 M | 74.1 M | 13.2 M | 16.3 M | - | - | - | 16.3 M | - | - | - | 3.16 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency